AAPG Overview

Ascentage Pharma Group International is an investment holding company primarily engaged in the discovery, development, and commercialization of therapies for hematologic malignancies. The Company's main products include Olverembatinib (HQP1351), Lisaftoclax (APG-2575), Alrizomadlin (APG-115), Pelcitoclax (APG-1252), APG-5918, and APG-2449. The Company's products are primarily used to treat chronic myeloid leukemia (CML), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS) and multiple myeloma (MM). The Company primarily conducts its businesses in domestic market.

Wall Street analysts forecast AAPG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AAPG is48.67 USD with a low forecast of 45.00 USD and a high forecast of 51.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Ascentage Pharma Group International revenue for the last quarter amounts to NaN USD, decreased

Ascentage Pharma Group International. EPS for the last quarter amounts to USD, decreased

Ascentage Pharma Group International (AAPG) has 767 emplpoyees as of May 30 2026.

Today AAPG has the market capitalization of 1.95B USD.